How should procurement teams qualify a provider entering the Pharmaceutical Logistics Market?

Request lane-specific validation dossiers, 24-month excursion statistics and inspectorate audit history rather than headline capacity claims. Providers unable to produce deviation data by trade lane typically lack a mature quality management system [14]. Read More

What contract structures best protect shippers against temperature excursion liability?

Tie liability to documented deviation from a validated lane profile, not to product value alone. Cargo policies frequently exclude excursions where the shipper specified the packaging, so allocate qualification responsibility explicitly in the statement of work [9]. Read More

How do 3PL and 4PL engagement models differ in the Pharmaceutical Logistics Market?

A 3PL executes physical handling under the manufacturer's quality system; a 4PL orchestrates multiple subcontracted providers and owns network design. Choose 4PL only when internal quality oversight capacity exists to audit the orchestrator [20]. Read More

Are passive or active shipping containers more cost-effective?

Passive systems win below roughly 96 hours of transit and on high-volume repeatable lanes. Active containers justify their rental and charging overhead on long-haul, high-value or unpredictable routings where excursion cost exceeds container cost [17]. Read More

What integration challenges arise when connecting carrier telemetry to enterprise systems?

Sensor data must be reconciled against batch-level records before it becomes audit evidence, and most providers export proprietary formats. Budget for middleware and validation testing, which routinely consume more effort than the sensor deployment itself [5]. Read More

Which insurance considerations matter most in the Pharmaceutical Logistics Market?

Underwriters increasingly price premiums against historical lane telemetry rather than declared value alone. Shippers with clean multi-year excursion records can negotiate materially lower rates, making data retention a direct financial asset [18]. Read More

What emerging use case should investors watch beyond commercial distribution?

Decentralised clinical trials require investigational product delivery to patient homes with full comparator and returns accountability. Few providers combine depot management, patient scheduling and reverse handling under one quality system, leaving a defensible service gap [4]. Read More

Pharmaceutical Logistics Market (2026 - 2035)

ID: MRFR/PCM/10020-HCR 200 Pages Varsha More Last Updated: September 15, 2026

Pharmaceutical Logistics Market Research Report Information By Service Type (Transportation, Road Freight, Air Freight, Sea Freight, Rail Freight, Warehousing & Storage, and Value-added Services and Others), By Mode of Operation (Cold-Chain Logistics and Non-Cold-Chain Logistics), and By Product Type (Prescription Drugs, OTC Drugs, Biologics & Biosimilars, Vaccines & Blood Products, Clinical Trial Materials, Cell & Gene Therapies, Medical Devices & Diagnostics, Veterinary Medicine, and Others) – Forecast Till 2035

Pharmaceutical Logistics Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)5.85%

2025 Market SizeUSD 600.07 Billion

2035 Market SizeUSD 1,059.54 Billion

Key Players

DHL Group

UPS Healthcare

FedEx Corporation

Kuehne+Nagel

DSV

CEVA Logistics

Trends

Biologics and Specialty Pipeline Expansion
Serialisation and Traceability Mandates
Temperature-Controlled Capital Deployment

Opportunities

Cryogenic Network Densification for Advanced Therapies
Data Monetisation Through Control-Tower Platforms
Emerging-Market Capacity Build-Out

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary | |
1. 1.1 Study Assumptions & Market Definition | |
2. 1.2 Scope of the Study | |
3. 1.3 Research Methodology | |
2 Key Report Takeaways | |
1. 2.1 By Service Type | |
2. 2.2 By Mode of Operation | |
3. 2.3 By Product Type | |
4. 2.4 By Region | |
3 Market Size and Forecast (2021–2035) | |
1. 3.1 Historical Market Size (2021–2025) | |
2. 3.2 Current & Forecast Market Size (2026–2035) | |
3. 3.3 Market Size by Revenue (USD Billion) | |
4. 3.4 Year-over-Year Growth Analysis | |
4 Driver Impact Analysis | |
1. 4.1 Biologics and Specialty Pipeline Expansion | |
2. 4.2 Serialisation and Traceability Mandates | |
3. 4.3 Temperature-Controlled Capital Deployment | |
4. 4.4 Direct-to-Patient and E-Pharmacy Distribution | |
5. 4.5 IoT Telemetry and AI Network Optimisation | |
6. 4.6 Cell and Gene Therapy Commercialisation | |
7. 4.7 Emerging-Market Immunisation Programmes | |
5 Restraints Impact Analysis | |
1. 5.1 Cold-Chain Energy and Fuel Cost Inflation | |
2. 5.2 Fragmented Multi-Jurisdiction Compliance | |
3. 5.3 Air Cargo Capacity and Rate Volatility | |
4. 5.4 Qualified Personnel Shortage | |
5. 5.5 Counterfeit Infiltration and Last-Mile Security Gaps | |
6 Opportunities | |
1. 6.1 Cryogenic Network Densification for Advanced Therapies | |
2. 6.2 Data Monetisation Through Control-Tower Platforms | |
3. 6.3 Emerging-Market Capacity Build-Out | |
4. 6.4 Sustainable Modal Shift to Ocean and Rail | |
5. 6.5 Integrated Clinical-Trial and Direct-to-Patient Services | |
7 Regional Market Share and Country-Level Analysis | |
1. 7.1 North America | | |
  1. 7.1.1 United States | | |
  2. 7.1.2 Canada | | |
  3. 7.1.3 Mexico | |
2. 7.2 Europe | | |
  1. 7.2.1 United Kingdom | | |
  2. 7.2.2 Germany | | |
  3. 7.2.3 France | | |
  4. 7.2.4 Spain | | |
  5. 7.2.5 Italy | | |
  6. 7.2.6 BENELUX (Belgium, Netherlands, and Luxembourg) | | |
  7. 7.2.7 NORDICS (Denmark, Finland, Iceland, Norway, and Sweden) | | |
  8. 7.2.8 Rest of Europe | |
3. 7.3 Asia-Pacific | | |
  1. 7.3.1 India | | |
  2. 7.3.2 China | | |
  3. 7.3.3 Japan | | |
  4. 7.3.4 Australia | | |
  5. 7.3.5 South Korea | | |
  6. 7.3.6 Southeast Asia (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines) | | |
  7. 7.3.7 Rest of Asia-Pacific | |
4. 7.4 South America | | |
  1. 7.4.1 Brazil | | |
  2. 7.4.2 Peru | | |
  3. 7.4.3 Chile | | |
  4. 7.4.4 Argentina | | |
  5. 7.4.5 Rest of South America | |
5. 7.5 Middle East and Africa | | |
  1. 7.5.1 United Arab Emirates | | |
  2. 7.5.2 Saudi Arabia | | |
  3. 7.5.3 South Africa | | |
  4. 7.5.4 Nigeria | | |
  5. 7.5.5 Rest of Middle East And Africa | |
8 Future Outlook (2026–2035) | |
1. 8.1 Predictive Quality and Autonomous Exception Management | |
2. 8.2 Platform Economics and Network Aggregation | |
3. 8.3 Decarbonisation of Temperature-Controlled Assets | |
4. 8.4 Regionalised Inventory and Manufacturing Proximity | |
9 Segmentation Analysis | |
1. 9.1 By Service Type | | |
  1. 9.1.1 Transportation | | |
  2. 9.1.2 Warehousing & Storage | | |
  3. 9.1.3 Value-added Services and Others | |
2. 9.2 By Mode of Operation | | |
  1. 9.2.1 Cold-Chain Logistics | | |
  2. 9.2.2 Non-Cold-Chain Logistics | |
3. 9.3 By Product Type | | |
  1. 9.3.1 Prescription Drugs | | |
  2. 9.3.2 OTC Drugs | | |
  3. 9.3.3 Biologics & Biosimilars | | |
  4. 9.3.4 Vaccines & Blood Products | | |
  5. 9.3.5 Clinical Trial Materials | | |
  6. 9.3.6 Cell & Gene Therapies | | |
  7. 9.3.7 Medical Devices & Diagnostics | | |
  8. 9.3.8 Veterinary Medicine | | |
  9. 9.3.9 Others | |
10 Competitive Landscape | |
1. 10.1 Market Share Analysis (2026) | |
2. 10.2 Competitive Benchmarking Matrix | |
3. 10.3 Company Profiles | |
11 Recent News & Developments | |
12 Report Scope and Methodology | |
13 Detailed Sources and Citations | |
14 Frequently Asked Questions (FAQs) | | LIST OF TABLES | |
TABLE 1 Global Pharmaceutical Logistics Market Size & Forecast, by Revenue (USD Billion), 2021–2035 | |
TABLE 2 Global Pharmaceutical Logistics Market — Year-over-Year Growth Analysis, 2021–2035 | |
TABLE 3 Driver Impact Analysis — Global Pharmaceutical Logistics Market, 2026–2035 | |
TABLE 4 Restraint Impact Analysis — Global Pharmaceutical Logistics Market, 2026–2035 | |
TABLE 5 Global Pharmaceutical Logistics Market Size, by Service Type, 2021–2035 (USD Billion) | |
TABLE 6 Global Pharmaceutical Logistics Market Size, by Mode of Operation, 2021–2035 (USD Billion) | |
TABLE 7 Global Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 8 Global Pharmaceutical Logistics Market Size, by Region, 2021–2035 (USD Billion) | |
TABLE 9 North America Pharmaceutical Logistics Market Size, by Country, 2021–2035 (USD Billion) | |
TABLE 10 Europe Pharmaceutical Logistics Market Size, by Country, 2021–2035 (USD Billion) | |
TABLE 11 Asia-Pacific Pharmaceutical Logistics Market Size, by Country, 2021–2035 (USD Billion) | |
TABLE 12 South America Pharmaceutical Logistics Market Size, by Country, 2021–2035 (USD Billion) | |
TABLE 13 Middle East and Africa Pharmaceutical Logistics Market Size, by Country, 2021–2035 (USD Billion) | |
TABLE 14 North America Pharmaceutical Logistics Market Size, by Service Type, 2021–2035 (USD Billion) | |
TABLE 15 North America Pharmaceutical Logistics Market Size, by Mode of Operation, 2021–2035 (USD Billion) | |
TABLE 16 North America Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 17 Europe Pharmaceutical Logistics Market Size, by Service Type, 2021–2035 (USD Billion) | |
TABLE 18 Europe Pharmaceutical Logistics Market Size, by Mode of Operation, 2021–2035 (USD Billion) | |
TABLE 19 Europe Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 20 Asia-Pacific Pharmaceutical Logistics Market Size, by Service Type, 2021–2035 (USD Billion) | |
TABLE 21 Asia-Pacific Pharmaceutical Logistics Market Size, by Mode of Operation, 2021–2035 (USD Billion) | |
TABLE 22 Asia-Pacific Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 23 South America Pharmaceutical Logistics Market Size, by Service Type, 2021–2035 (USD Billion) | |
TABLE 24 South America Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 25 Middle East and Africa Pharmaceutical Logistics Market Size, by Service Type, 2021–2035 (USD Billion) | |
TABLE 26 Middle East and Africa Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 27 United States Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 28 Germany Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 29 China Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 30 India Pharmaceutical Logistics Market Size, by Product Type, 2021–2035 (USD Billion) | |
TABLE 31 Competitive Benchmarking Matrix — Global Pharmaceutical Logistics Market, 2026 | |
TABLE 32 Company Profiles — Key Players, Global Pharmaceutical Logistics Market | |
TABLE 33 Recent Developments & Strategic Announcements, 2023–2025 | |
TABLE 34 Report Scope & Methodology — Global Pharmaceutical Logistics Market | |
TABLE 35 Detailed Sources and Citations | | LIST OF FIGURES | |
FIGURE 1 Market Dynamics — Drivers, Restraints and Opportunities, Global Pharmaceutical Logistics Market | |
FIGURE 2 Industry Value Chain Analysis, Global Pharmaceutical Logistics Market | |
FIGURE 3 Porter's Five Forces Analysis, Global Pharmaceutical Logistics Market | |
FIGURE 4 Global Pharmaceutical Logistics Market Size Trend, 2021–2035 (USD Billion) | |
FIGURE 5 Year-over-Year Growth Trend, 2021–2035 (%) | |
FIGURE 6 Market Share by Service Type, 2025 vs 2035 (%) | |
FIGURE 7 Market Share by Mode of Operation, 2025 vs 2035 (%) | |
FIGURE 8 Market Share by Product Type, 2025 (%) | |
FIGURE 9 Regional Market Share, 2025 vs 2035 (%) | |
FIGURE 10 Country-Level Share within Europe, 2025 (%) | |
FIGURE 11 Country-Level Share within Asia-Pacific, 2025 (%) | |
FIGURE 12 Competitive Landscape — Estimated Revenue Share Bands, 2026 | |
FIGURE 13 Competitive Positioning Matrix — Reach vs Validated Capacity | |
FIGURE 14 Forecast Scenario Analysis, 2026–2035

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Service Type	Transportation (Road Freight, Air Freight, Sea Freight, Rail Freight); Warehousing & Storage; Value-added Services and Others	Transportation — 54.90% share (2025)	Value-added Services and Others — 4.73% CAGR (2026–2035)
By Mode of Operation	Cold-Chain Logistics; Non-Cold-Chain Logistics	Non-Cold-Chain Logistics — 68.70% share (2025)	Cold-Chain Logistics — 5.96% CAGR (2026–2035)
By Product Type	Prescription Drugs; OTC Drugs; Biologics & Biosimilars; Vaccines & Blood Products; Clinical Trail Materials; Cell & Gene Therapies; Medical Devices & Diagnostics; Veterinary Medicine; Others	Prescription Drugs — 32.70% share (2025)	Cell & Gene Therapies — 6.55% CAGR (2026–2035)

Market Segmentation Overview

By Service Type

Sub-Segment	Key Trend
Transportation	Modal rebalancing as ocean and rail absorb stable-product volume from air
Road Freight	Densifying regional replenishment networks across Europe and North America
Air Freight	Premium pricing sustained by biologic and clinical-trial urgency
Sea Freight	GDP-compliant reefer qualification unlocking multi-week lanes
Rail Freight	Intermodal corridors gaining share on emissions and cost grounds.
Warehousing & Storage	Certified multi-zone chamber shortage driving new campus construction
Value-added Services and Others	Serialisation consulting and relabelling shifting from optional to mandatory

Transportation leads at 54.90% because physical movement remains the irreducible core of the service, and within it Road Freight carries the largest regional volume while Air Freight commands the premium on time-critical biologic lanes. Value-added Services and Others grows fastest as data-integrity rules turn certified relabelling and tamper-evident pack-out into procurement prerequisites rather than extras. Contract manufacturers in Asia-Pacific are the most active buyers of these services, seeking single-source partners for multilingual regulatory printing. Warehousing & Storage sits between the two, constrained less by demand than by the availability of certified chamber capacity.

By Mode of Operation

Sub-Segment	Key Trend
Cold-Chain Logistics	Multi-zone hybrid facilities and cryogenic micro-segment expansion
Non-Cold-Chain Logistics	Volume-led ambient distribution facing utility-style price convergence

Non-Cold-Chain Logistics retains 68.70% of throughput on solid-dose and consumer-health volume, but it competes largely on cost and is the segment most exposed to platform-driven price compression. Cold-Chain Logistics grows faster at 5.96% because biologics, vaccines and specialty injectables all require validated 2 °C–8 °C or cryogenic handling that few operators can certify. Hybrid distribution centres with switchable chambers now let providers serve both modes from one footprint, improving asset utilisation. Ultra-low and cryogenic handling remains the highest-margin niche within the cold segment.

By Product Type

Sub-Segment	Key Trend
Prescription Drugs	Precision-medicine launches pushing items from ambient into refrigerated routing.
OTC Drugs	E-commerce fulfilment reshaping pack sizes and delivery frequency
Biologics & Biosimilars	Lane densification enabling dry-ice and phase-change material pooling.
Vaccines & Blood Products	Programme-driven demand tied to national and donor procurement cycles
Clinical Trial Materials	Decentralised trial designs multiplying delivery points per protocol.
Cell & Gene Therapies	Cryogenic preservation and chain-of-identity commanding premium rates
Medical Devices & Diagnostics	Point-of-care testing expanding ambient distribution volume.
Veterinary Medicine	Companion-animal biologics introducing refrigerated requirements
Others	Ancillary and nutraceutical flows using shared network capacity

Prescription Drugs anchor the dimension at 32.70% because mature wholesaler and pharmacy channels handle enormous unit volume at predictable cost, though a rising share of prescription items now requires refrigerated routing. Cell & Gene Therapies grow fastest at 6.55% despite a small revenue base, since each autologous shipment demands validated −196 °C holding, GPS-enabled dry shippers and pick-up synchronised to manufacturing release. Biologics & Biosimilars sit between them, adding enough refrigerated lane density to make dry-ice replenishment economic at scale. Providers unable to certify cryogenic handling will find themselves confined to the slower-growing ambient categories.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”